Johnson & Johnson strengthens its commitment in Italy: 580 million euros in the next five years, including 125-million-euro investments to support production at Latina plant

The announced investment in manufacturing will increase capacity to deliver the company's portfolio of innovative therapies for patients around the world.

According to a new study by The European House – Ambrosetti, the company generates a significant direct and indirect impact on the Italian economy with the activation of **more than 7,000 jobs**.

Rome, June 14th, 2024 - Johnson & Johnson Innovative Medicine¹ today announced its strengthened commitment in Italy, with a projected investment of 580 million euros over the next five years, of which 125 million euros will support an increase in production capacity and build capabilities for the future.

The investment announcement is part of a strategic plan that has included a **9.2 per cent investment growth each year** between 2019-2023 in Italy, which is three times greater than the pharmaceutical sector average, according to a new study by The European House – Ambrosetti². Additionally, this investment has translated to a **15 percent increase in** employment in Italy over the last five years to about 1,400 employees throughout the country.

In the pharmaceutical landscape, Johnson & Johnson stands out for its **strong focus on R&D**: in the last five years, the company **invested nearly 50 million euros in Italy (+11,7 per cent** each year since 2019). The investments in R&D also favor a strong commitment towards scientific research in the country. In 2023, Johnson & Johnson Innovative Medicine managed **114 clinical trials** and collaborated with **993 research centers** in Italy, offering treatment access to more than **5,000 patients**.

The Latina site is an important part of Johnson & Johnson's global supply chain network. The site produces more than **four billion tablets every year, for about 30 different products, with 97 per cent of its production exported, reaching patients from worldwide.**

The investment plan will enable a production **capacity increase of more than 25 per cent**, as it includes innovative **projects to support pipeline products and new production technologies**, such as a Flex Line, to more efficiently handle the packaging of small production batches and a new continuous manufacturing line that will reduce total end-to-end manufacturing time and enable medicines to reach patients more quickly.

"The Johnson & Johnson site in Latina, Italy, is undergoing a significant evolution as we enhance our capabilities to serve more patients with innovative products. It has been designated as a 4IR (Industry 4.0 site) by the World Economic Forum due to our commitment to innovation and sustainability. Times are very exciting for our site. We have a highly passionate and committed workforce, who are focused on safety, quality, and reliability as we work to provide medicines for patients around the world every single day" – commented **Jorge Lopez**, General Manager of the Johnson & Johnson Latina Plant.

"Johnson & Johnson has a significant manufacturing presence across Europe and the Latina site is an important part of our global network," said **Dapo Ajayi**, Vice President, Innovative Medicine Supply Chain at Johnson & Johnson. "We continue making important investments in our Supply Chain to support the growth of our current portfolio of medicines and our pipeline of new innovations, which will enable us to continue to deliver for the millions of patients around the world who rely on us every day."


¹ Formerly Janssen, pharmaceutical company of Johnson & Johnson

²The European House – Ambrosetti - Johnson & Johnson Innovative Medicine's contribution to the country's innovation system and growth, 2024

"Since 1975, we have been a strongly rooted company in Italy. With this extraordinary investment we strengthen our concrete commitment to foster and increase the attractiveness and competitiveness of the country, by reinforcing research and pharmaceutical production excellence. We trust that innovation will continue to be welcomed and properly recognized, that the clinical trials ecosystem will improve and get faster and that constructive dialogue between institutions and the industry – already opened by the Government – continues and remains open. Every day, we work together with all our stakeholders of the healthcare system to contribute to the development of the sector, with the aim of bringing innovation to our patients and the National Health System" - underlines **Mario Sturion**, Managing Director of Johnson & Johnson Innovative Medicine Italy.

"Today's press conference demonstrates how the pharmaceutical sector has become a new growth model for Made in Italy, thanks to the impressive investments in research and innovation. This growth is 60% driven by foreign companies and allows the local supply chain to grow and promotes its internationalization. This is a sector that can give great satisfaction in "opening Italy to the world" and "bringing the world to Italy". Following the European elections, Italy has become one of the most reliable countries at European level, capable of attracting more and more foreign investments" – **Minister of Enterprises and Made in Italy Adolfo Urso** said.

"The announcement by Johnson & Johnson, which will invest 580 million euros in Italy over the next 5 years, is further proof that the pharmaceutical industry continues to firmly believe in our nation", **Marcello Cattani, President of Farmindustria** (national trade association) declares. "It is not a coincidence that production of the sector exceeded 50 billion euros, 49 for export. In Italy, pharmaceutical employment, especially among young people and women, continues to grow, reaching 70,000 workers. These data come from over 3.5 billion investments in the sector, which demonstrate the deep roots in the territory of both international and national companies. With new rules capable of attracting investments, even more can be done. A path that the Italian Government is following, because it considers the Life Sciences sector important and strategic".



ABOUT JOHNSON & JOHNSON

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.janssen.com/johnson-johnson-innovative-medicine. Follow us at @JanssenUS and @JNJInnovMed.

ABOUT JOHNSON & JOHNON INNOVATIVE MEDICINE IN ITALY

Johnson & Johnson Innovative Medicine is part of the Johnson & Johnson Group. Present in Italy since 1975, it is led by Mario Sturion as Managing Director. Innovative Medicine operates in Italy with 1,400 people based in its headquarters in Milan and its production site in Latina (near Rome), one of the most innovative in the world. It focuses its activities in six key therapeutic areas for global health: onco-hematology, immunology, neuroscience, pulmonary arterial hypertension, infectious diseases and vaccines, and cardiovascular, metabolic and retinal diseases. The company has committed to innovation since its foundation: the the World Health Organization, in fact, has included 18 molecules developed by Johnson & Johnson research on the list of "essential medicines for humanity."